Is C4 Therapeutics, Inc. (CCCC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 22.3% / 30% | 83.1% / 30% | 1.1% / 30% | 40.55% / 5% | ✗ NOT HALAL |
| DJIM | 22.3% / 33% | 83.1% / 33% | 1.1% / 33% | 40.55% / 5% | ✗ NOT HALAL |
| MSCI | 18.8% / 33% | 70.1% / 33% | 0.9% / 33% | 40.55% / 5% | ✗ NOT HALAL |
| S&P | 22.3% / 33% | 83.1% / 33% | 1.1% / 33% | 40.55% / 5% | ✗ NOT HALAL |
| FTSE | 18.8% / 33% | 70.1% / 33% | 0.9% / 50% | 40.55% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 75.0% | |
| Operating Margin | -210.1% | |
| Net Margin | -292.1% | |
| Return on Equity (ROE) | -44.4% | |
| Return on Assets (ROA) | -18.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$99M |
| Free Cash Flow | -$99M |
| Total Debt | $60M |
| Debt-to-Equity | 23.4 |
| Current Ratio | 7.8 |
| Total Assets | $359M |
Price & Trading
| Last Close | $2.62 |
| 50-Day MA | $2.39 |
| 200-Day MA | $2.32 |
| Avg Volume | 2.0M |
| Beta | 2.9 |
|
52-Week Range
$1.08
| |
About C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is C4 Therapeutics, Inc. (CCCC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), C4 Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is C4 Therapeutics, Inc.'s debt ratio?
C4 Therapeutics, Inc.'s debt ratio is 22.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 18.8%.
What are C4 Therapeutics, Inc.'s key financial metrics?
C4 Therapeutics, Inc. has a market capitalization of $235M, and revenue of $36M. The company maintains a gross margin of 75.0% and a net margin of -292.1%. Return on equity stands at -44.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.